

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	nation				
1. Given Name (Fir Marcus A	rst Name)	2. Surnar Mall	ne (Last Nam	e)		3. Date 18-June-2019
4. Are you the cor	responding author?	Yes ✓ No Corresponding Author's Name Clifford Taggart				
5. Manuscript Title Targeting protea	ses in cystic fibrosis lui	ng disease:	paradigms,	progress and p	otential	
6. Manuscript Ider Blue-201906-119	ntifying Number (if you kr 10PP	now it)				
Section 2.						
	The Work Under C	onsiderat	tion for Pu	blication		
	ubmitted work (including					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
•	evant conflicts of intere					
	out the appropriate info oe removed by pressin		•	have more thar	one enti	ity press the "ADD" button to add a row.
Name of Institut	ion/Company	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
German Federal Minis Research	stry of Education and	✓				Grant # 82DZL004A1
German Research Fou	ındation	\checkmark				Grant # SFB-TR84TP B08
Einstein Foundation E	Berlin	\checkmark				Grant # EP-2017-393
Section 3.	Relevant financial	activities	outside tl	ne submitted	work.	
of compensation) with entities as descri	bed in the	instructions	s. Use one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by a 86 months prior to publication .
_	evant conflicts of intere		·	-	-	- · ·
If yes, please fill o	out the appropriate info	ormation b	elow.			
Name of Entity		Grant?	Personal Fees?	Non-Financial Support	Other?	Comments
Bayer			✓			Consultancy, Lecture fee



Name of Entity	Gra	ant•	ersonal Fees	Non-Financial Support?	Other?	Comments
Boehringer Ingelheim			√			Advisory Board, Consultancy, Lecture fees
Polyphor			✓			Advisory Board, Consultancy
Arrowhead Pharmaceuticals			✓			Advisory Board, Consultancy
ProQR Therapeutics			✓			Advisory Board, Consultancy
Spyryx Biosciences			✓			Advisory Board, Consultancy
Vertex Pharmaceuticals			✓			Advisory Board, Consultancy, Lecture fees
Santhera			✓			Advisory Board, Consultancy
Galapagos			✓			Consultancy
Sterna Biologicals			✓			Consultancy
Enterprise Therapeutics			✓			Advisory Board, Consultancy
 Celtaxys			√			Lecture fee
Do you have any patents, whet	riate informat	pending tion belo	or issued	d, broadly releva		work?
Patent?	Pending?	Issued	License	ed? Royalties?	License	ee? Comments
Patent on the Scnn1b-transgenic mouse		V		V		M.A.M. is listed on a patent filed by the University of North Carolina at Chapel Hill, describing the Scnn1b-transgenic mouse. Of note, the Scnn1b-transgenic mouse has been deposited at JAX for general disposition.
Patent on use of sodium channel blockers for early therapy of obstructive lung diseases		V				M.A.M. is listed on a patent filed by the University of Heidelberg describing use of sodium channel blockers for early therapy of obstructive lung diseases.



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
c .: .	
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Dr. Mall reports grants from German Federal Ministry of Education and Research, grants from German Research Foundation, grants from Einstein Foundation Berlin, during the conduct of the study; personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Polyphor, personal fees from Arrowhead Pharmaceuticals, personal fees from ProQR Therapeutics, personal fees from Spyryx Biosciences, personal fees from Vertex Pharmaceuticals, personal fees from Santhera, personal fees from Galapagos, personal fees from Sterna Biologicals, personal fees from Enterprise Therapeutics, personal fees from Celtaxys, outside the submitted work; In addition, Dr. Mall has a patent Patent on the Scnn1b-transgenic mouse with royalties paid, and a patent Patent on use of sodium channel blockers for early therapy of

Evaluation and Feedback

obstructive lung diseases issued.

below.

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	ation								
1. Given Name (First Name) Daniel F		me (Last Nan y	ne)		3. Date 17-October-2019				
4. Are you the corresponding author?	Yes	✓ No	•	Corresponding Author's Name Cliff Taggart					
5. Manuscript Title Targeting proteases in cystic fibrosis lung disease: paradigms, progress and potential									
6. Manuscript Identifying Number (if you know it)									
Section 2. The Work Under Co	nsidera	tion for P	ublication						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No									
Section 3. Relevant financial activities outside the submitted work.									
Place a check in the appropriate boxes in of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	oed in the ort relation st?	e instructior onships tha Yes	ns. Use one line fo t were present d No	or each er uring the	ntity; add as many lines as you need by				
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Bayer		✓			Consultancy for treatment of ARDS				
NIHR, Wellcome Trust and other funders	✓				Investigator in studies investigating new treatments in ARDS				
GlaxoSmithKline		\checkmark			Consultancy for treatments of ARDS				
GlaxoSmithKline				✓	Payment to institution for undertaking bronchoscopy undertaken as part of this clinical trial				
Boehringer Ingelheim		✓			Consultancy for treatment of ARDS				



Section 4. Intellectual						
Intellectual	Property Paten	ts & Copyrights				
Do you have any patents, wheth If yes, please fill out the approp Excess rows can be removed by	riate information bel	ow. If you have more		Yes No s the "ADD" button to add a	a row.	
Patent?	Pending? Issued	Cicensed Royaltic	Licensee?	Comments		
Patent for novel treatment for ARDS			Queen's University Belfast	Patent submitted for novel treatment for ARDS		
Section 5. Bolotionshi						
Relationshi	ps not covered at	oove				
Are there other relationships or potentially influencing, what yo			ave influenced, or th	at give the appearance of		
Yes, the following relationsh	nips/conditions/circu	mstances are present	(explain below):			
\checkmark No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript accep On occasion, journals may ask a	-		· · · · · · · · · · · · · · · · · · ·		nents	
Section 6. Disclosure S	********					
Based on the above disclosures, below.		natically generate a di	sclosure statement,	which will appear in the bo	×	
Outside the submitted w	ork, Dr McAuley	reports persona	I fees from cons	ultancy for		

Outside the submitted work, Dr McAuley reports personal fees from consultancy for GlaxoSmithKline, Boehringer Ingelheim and Bayer, Outside the submitted work, his institution has received funds from grants from the UK NIHR, Wellcome Trust and others and from GlaxoSmithKline for Dr McAuley undertaking bronchoscopy as part of a clinical trial. In addition, Dr. McAuley is one of four named inventors on a patent US8962032 covering the use of sialic acid–bearing nanoparticles as anti-inflammatory agents issued to his institution, The Queen's University of Belfast (http://www.google.com/patents/US8962032). This has no direct impact on the contents of the manuscript.



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1				
Section 1. Identifying Inform	ation			
Given Name (First Name) Clifford	2. Surname (Last N Taggart	lame)		3. Date 18-June-2019
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title Targeting proteases in cystic fibrosis lur	ng disease:paradigi	ms, progress and p	ootential	
6. Manuscript Identifying Number (if you kn Blue-201906-1190PP	ow it)			
Section 2. The Work Under Co	onsideration for	Publication		
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to gi			
If yes, please fill out the appropriate info	ormation below. If y	_	ın one entity p	press the "ADD" button to add a row.
Excess rows can be removed by pressing				
Name of Institution/Company	Grant? Person	_	Other? C	omments
Medical Research Council	√			
Rosetrees Trust	✓			
Northern Ireland Department of the Economy	✓			
Section 3. Relevant financial	activities outsid	e the submitted	l work.	
Place a check in the appropriate boxes in of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instruct	ons. Use one line	for each entity	y; add as many lines as you need by
Are there any relevant conflicts of intere	est? 🗸 Yes	No		
If yes, please fill out the appropriate info	ormation below.			
Name of Entity	Grant? Person	Non-Financia	Other? C	omments
Pfizer UK				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Chiesi	✓					
Randox Diagnostics						
Benevolent Al						
Section 4. Intellectual Propert	y Pate	ents & Cop	oyrights			
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the v	work? Yes V No	
Section 5. Relationships not o	overed	above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	w):	
✓ No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						nents.
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this forn below.	n will auto	omatically (generate a disclos	sure state	ment, which will appear in the box	
Dr. Taggart reports grants from Medical Department of the Economy, during the Diagnostics, from Benevolent AI, outsic	e conduct	t of the stud	dy; grants from Pf		•	



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform				
Identifying Inform	ation			
1. Given Name (First Name) Sinead	2. Surname (Last Name) Weldon		3. Date 19-June-2019	
4. Are you the corresponding author?	Yes 🗸 No	or's Name		
5. Manuscript Title Targeting proteases in cystic fibrosis lun	ng disease:paradigms, pro	ogress and potential		
6. Manuscript Identifying Number (if you kn Blue-201906-1190PP	ow it)			
Section 2. The Work Under Co	onsideration for Publ	ication		
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, dest? Yes No	ata monitoring board, st	udy design, manuscript preparation,	
If yes, please fill out the appropriate info Excess rows can be removed by pressing		ve more than one enti	ty press the "ADD" button to add a ro	w.
Name of Institution/Company	Grant? Personal No	on-Financial Other?	Comments	
Medical Research Council				
Rosetrees Trust				
Cystic Fibrosis Foundation				
Section 3. Relevant financial	activities outside the	submitted work.		
Place a check in the appropriate boxes in of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions. U	Jse one line for each er	ntity; add as many lines as you need b	
Are there any relevant conflicts of intere	est? ✓ Yes No			
If yes, please fill out the appropriate info	rmation below.			
Name of Entity	Grant? Personal No	on-Financial Other?	Comments	
Pfizer UK				



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments		
Randox Diagnostics	\checkmark					
Benevolent Al	✓					
Section 4. Intellectual Propert	y Patents & Co	pyrights				
Do you have any patents, whether planne	ed, pending or issu	ed, broadly releva	nt to the v	work? Yes 🗸 No		
Section 5. Relationships not co	overed above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, joi On occasion, journals may ask authors to					ments.	
Section 6. Disclosure Statemen	nt					
Based on the above disclosures, this form below.	n will automatically	generate a disclos	ure state	nent, which will appear in the bo	x	
Dr. Weldon reports grants from Medical Foundation, during the conduct of the s Benevolent AI, outside the submitted we	study; grants from P			,		



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

McKelvey 1



Section 1.	Identifying Inform	ation				
1. Given Name (Fi Michael	rst Name)	2. Surname (Last Name) McKelvey		3. Date 18-June-2019		
4. Are you the cor			Corresponding Author's Name Clifford Taggart			
5. Manuscript Title Targeting protea		g disease: paradigms, pro	ogress and potential			
6. Manuscript Idea	ntifying Number (if you kn 90PP	ow it)				
Section 2.	The Work Under Co	onsideration for Public	cation			
any aspect of the s statistical analysis, Are there any rel If yes, please fill o Excess rows can	ubmitted work (including etc.)? evant conflicts of intere out the appropriate info be removed by pressing	st? Yes No rmation below. If you have the "X" button. Grant? Personal No	ta monitoring board, st	ent, commercial, private foundation, etc.) for tudy design, manuscript preparation, ity press the "ADD" button to add a row. Comments Studentship		
Section 3.	Relevant financial a	activities outside the s	submitted work			
of compensation clicking the "Adc Are there any rel	the appropriate boxes in) with entities as descril	n the table to indicate whoed in the instructions. Used in the instructions. Used the twenty in the	ether you have finan se one line for each e	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.		
Section 4.	Intellectual Proper	ty Patents & Copyric	yhts			
Do you have any	patents, whether planr	ned, pending or issued, br	oadly relevant to the	work? Yes V No		

McKelvey 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Mr. McKelvey reports studentship funding from the Northern Ireland Department for the Economy, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

McKelvey 3